DFFN
Diffusion Pharmaceuticals Inc.
Set alert
4.40 0.00 0.00%
4.17 Day range 5.19
52-week range unavailable
- Open
- 4.23
- Prev close
- 4.40
- Mkt cap
- 6.30M
- Vol
- 349.44K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.17
- High
- 5.19
- Forward P/E
- -0.42
- Beta
- 1.77
- Short ratio
- 0.16
- Inst. own
- 9.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2023
- 50-d avg
- 3.66
- 200-d avg
- 5.05
- 1y target
- 40.00
Key statistics
- Market cap
- 6.30M
- Enterprise value
- -11.68M
- Trailing P/E
- 0.00
- Forward P/E
- -0.42
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.39
- EPS (TTM)
- -7.66
- Beta
- 1.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.04M
- Total cash
- 17.64M
- Total debt
- 0
- Return on equity
- -64.64%
- Shares outstanding
- 2.04M
- Short % of float
- 0.07%
- 50-day average
- 3.66
- 200-day average
- 5.05
Analyst view
Consensus: buy
Buy
Price target (mean) 40.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2023
Expected Aug 8, 2023. Consensus EPS estimate 0.00.
Financials — quick view
DFFN Revenue — quarterly 0
DFFN Net income — quarterly -4.09M
DFFN EPS — quarterly -1.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Apr 3, 2023 | Dec 1, 2022 | -2.20 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -2.06 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.77 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.75 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2022 | HC Wainwright & Co. | up | Neutral | Buy |
| Nov 17, 2020 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 17, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Nov 25, 2020 | H.C. Wainwright | reit | — | Buy |
| Nov 25, 2020 | H.C. Wainwright | init | — | Buy |
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- diffusionpharma.com
News
- CervoMed Announces Completion of Merger with EIP Pharma
- Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Wednesday
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
- Stocks That Hit 52-Week Lows On Monday
- DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN
- DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders
- Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Your note
Sign in to keep a note on DFFN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ROBERT W | Director | Stock Award(Grant) | Jan 7, 2016 | 0 |
| BYRNE THOMAS S JD | Director | Stock Award(Grant) | Jan 7, 2016 | 1,391,870 |
| COBUZZI ROBERT JOSEPH JR | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 30, 2023 | 1,616 |
| ELDER WILLIAM ROBERT | General Counsel | Conversion of Exercise of derivative security | Apr 17, 2022 | 400 |
| GAINER JOHN L. PHD | Officer and Director | Stock Award(Grant) | Jan 7, 2016 | 0 |
| GILES MARK T | Director | Purchase | Dec 27, 2016 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 3.57% | 72,763 | 224.84K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.92% | 39,109 | 120.85K | Mar 30, 2023 |
| Blackrock Inc. | 1.61% | 32,852 | 101.51K | Mar 30, 2023 |
| Citadel Advisors Llc | 0.91% | 18,657 | 57.65K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.84% | 17,123 | 52.91K | Mar 30, 2023 |
| Bridgeway Capital Management, Inc. | 0.81% | 16,565 | 51.19K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.01% | 41,002 | 126.70K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.42% | 28,978 | 89.54K | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.81% | 16,565 | 51.19K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.49% | 10,027 | 30.98K | Feb 27, 2023 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.30% | 6,099 | 18.84K | Jan 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.12% | 2,365 | 7.31K | Feb 27, 2023 |